Pepti Review: $99 Semaglutide, One Open Question

Pepti sells 68 prescription SKUs from a single account, and the two that will bring you here are injectable semaglutide at $99 a month and injectable tirzepatide at $199. Those are among the lowest published GLP-1 numbers we track anywhere. They are also the subject of a contradiction inside Pepti's own site that we could not resolve, and this review is going to spend more time on that than on anything else, because a $99 headline you cannot confirm is not a bargain — it is an open position.

What the site says you pay

The price is flat per SKU per month and identical at every titration dose. Injectable semaglutide is $99 a month; injectable tirzepatide is $199. A one-time purchase, if you would rather not subscribe, costs the monthly figure multiplied by 1.25 — $124 and $249 respectively, and that multiplier holds across the catalogue.¹ Cancellation is any time with no minimum term, effective at the end of the cycle, and a subscription can be paused for up to 90 days.²

Flat pricing across the titration ladder is genuinely unusual and genuinely valuable. Reaching a maintenance dose takes months, and at most providers the early months are the ones you overpay for per milligram. The titration planner shows how many billing cycles that climb actually takes; a provider that does not re-price you at each step is removing a real cost.

The open question

Pepti's own production data carries a second, per-dose price ladder that nothing on the site renders: semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549 across its four doses. No component on the page consumes it. Meanwhile Pepti's own cost page states, in as many words, that all doses carry one flat monthly price of $99.¹

We file the rendered $99 and $199, because that is what the page shows, what the catalogue object carries, and what the cost page and three cross-sell surfaces repeat. But a dead ladder averaging roughly three times the headline, sitting in the data a production site ships, is not nothing. The obvious way to break the tie is to walk the intake to a real checkout and read the charge — and the checkout endpoint accepts no request we could make of it, so we could not. We are recording this as unresolved rather than picking whichever answer flatters the story, and it is the single reason Pepti is not our recommendation on price alone. What a headline rate looks like when the monthly rung is filtered out covers the general shape of this failure; this is a variant we have not seen before.

Verify the charge on your first statement, not on the marketing page. That advice applies everywhere, and here it applies with force.

Thirty-six states, not fifty

Pepti's shipping page, its state-availability page, its providers page and its own homepage title all say the same thing: 36 states, and the list is published.³ Its terms of service say the service is available in all 50. Four surfaces against one, and the four are the ones that carry an actual list, so 36 is the number we treat as operative. If you are in one of the other fourteen, do not assume the terms page is the one telling the truth.

Confirming state coverage before you get attached to a brand is step six of our provider checklist, and this is a clean example of why the check has to be done against a list rather than a claim.

When the card is charged

The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before the licensed provider reviews your intake.⁴ Same site, opposite claims.

The refund policy is the operative document, so assume you are charged first and reviewed second. If a provider declines you, the policy promises a full refund in five to ten business days. Once medication ships there is no refund, which is standard for compounded prescriptions and explained in is compounded semaglutide legit and safe.

The catalogue is very large, and that cuts both ways

Beyond the injectables there are oral semaglutide at $249 and oral tirzepatide at $399, GLP-1 oral drops at $239 and a GLP-1/GIP drop at $349, and two low-dose longevity SKUs at $149 and $229. The peptide shelf runs from BPC-157 at $209 through a BPC-157 and TB-500 stack at $289, KPV at $229, sermorelin and tesamorelin at $189 each, CJC-1295 with ipamorelin at $239, NAD+ in three routes from $159 to $219, and GHK-Cu from $159 to $239. There is a DSIP sleep protocol at $189 a month. Blood panels are $199, or $169 on a plan.

Depth is a real feature if you want one account for several things. It is also where the problem is. Pepti's shelf includes retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form, in any jurisdiction — it is an investigational molecule still in trials, and a company selling it to consumers is selling something no regulator has cleared for the purpose. We do not treat any of those three as options a reader should be choosing between, and no board on this site will ever rank them. The federal ground under compounded supply is already moving, as the end of GLP-1 compounding sets out; an investigational shelf sitting beside a prescription one is exposure a patient inherits.

Who is behind it

Two prescribers are named with full biographies: Dr. Gene Lee, MD, the medical director, board-certified in family medicine and licensed in 26 named states, and Dr. Laeeq Butt, MD, MBA, the chief medical officer, internal medicine, licensed in 15. That is more disclosure than most of this cohort offers.

Neither publishes an NPI, which means neither can be checked against the national registry — the same registry where we confirmed The Edit's medical director in a few seconds. The pharmacy is never named at all, only described as an independent FDA-registered 503A or 503B facility. The legal entity is pepti LLC, at a Newark, Delaware address that is a registered-agent suite rather than an operating site.

We ran Pepti, its legal entity and its trading name through the FDA's live warning-letter index and found no company-column match.⁵ The pass carried a positive control — an unrelated telehealth seller with a real February 2026 letter — which returned correctly, so that zero is evidence rather than a silent query. Worth noting that the same search space is thick with peptide sellers who do carry letters; Pepti is not among them.

The ruling

At $99 a month flat across every dose, Pepti would be the cheapest credible semaglutide on our board and a strong candidate for the cash-price ruling. We are not prepared to write that sentence without the qualifier, because the company's own production data disagrees with its own headline by roughly threefold and we could not force an answer. Treat $99 as the price Pepti publishes, verify it on your first charge, and read Auren Rx and Trellis Vitality alongside it — both publish ladders with nothing hiding underneath. The rest of the reasoning behind how we weigh price honesty is in our published methodology.